the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

Mesothelioma Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
IRB16-1055 Kindler, Hedy A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma
Phase II
Study No PI Title
CIRB15-1357 Luke, Jason EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
IRB15-1223 Kindler, Hedy A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy Details
IRB14-1381 Kindler, Hedy A Phase II study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma Details
Phase I
Study No PI Title
IRB16-1743 Ratain, Mark An Open Label Phase I, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies
IRB16-0712 Kindler, Hedy An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination with Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects with Mesothelin-Expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
IRB15-1384 Kindler, Hedy A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) Details
IRB14-0592 Kindler, Hedy Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling Details
Study No PI Title
IRB15-1149 Kindler, Hedy A pilot window-of-opportunity study of the anti-PD-1 antibody pembrolizumab in patients with resectable malignant pleural mesothelioma Details
IRB13-1268 Kindler, Hedy Long-Term Follow-Up of Subjects who Have Participated in Aduro-Sponsored Protocols
11-0755 Kindler, Hedy The International Association for the Study of Lung Cancer IASLC Prospective Malignant Pleural Mesothelioma Staging Project
13473A Vokes, Everett Utilization of Previously Banked Tissue from Patients with Lung Cancer, Mesothelioma, Thymoma/Thymic Carcinoma, and Esophageal Cancer and Correlation with Clinical Data.
9571 Patel, Jyoti Tissue Procurement for Lung Cancer, Esophageal Cancer, Thymoma, and Mesothelioma in Patients Undergoing Surgery or Biopsy

Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .